Drug firm BDR Pharma on Wednesday said it has inked a licensing pact with Eli Lilly and Company for the manufacturing and distribution of Baricitinib for the treatment of COVID-19 in India.
The company said it has entered into a royalty-free, limited and non-exclusive voluntary licensing agreement with Eli Lilly and Company.
Baricitinib has received restricted emergency use approval, for use in combination with Remdesivir, for treatment of suspected or laboratory confirmed COVID-19 in hospitalised adults and pediatric patients two years of age or older, requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation.
Eli Lilly has received the permission for the drug for restricted emergency use from Central Drugs Standard Control Organization, a division of the Ministry of Health.

Related Keywords

India , Luca Visini , Dharmesh Shah , Eli Lilly , Ministry Of Health , Central Drugs Standard Control Organization , Chairman Dharmesh Shah , Drug Controller General , Lilly India Managing Director , India Subcontinent , Chemical Compounds , Organic Compounds , Heterocyclic Compounds , Zetidines , Baricitinib , Breakthrough Therapy , Pyrazoles , Sulfonamides , Eli Lilly And Company , Harmaceuticals Nec , Severe Active Rheumatoid Arthritis , Dr , இந்தியா , தர்மேஷ் ஷா , எலி லில்லி , அமைச்சகம் ஆஃப் ஆரோக்கியம் , மைய மருந்துகள் தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந் , மருந்து கட்டுப்படுத்தி ஜநரல் , இரசாயன கலவைகள் , டாக்டர் ,